Skip to main content

Advertisement

SpringerLink
Log in

Screening and Management of Hepatocellular Carcinoma: The Australian Perspective

  • Global Perspectives: Australia (W Sievert, Section Editor)
  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Hepatocellular cancer (HCC) remains relatively uncommon in Australia, however incidence rates have been progressively rising, as in many other western countries, over the last few decades. Currently, chronic hepatitis B (HBV) or hepatitis C (HCV) infections accounts for the majority of primary liver cancers, but as the incidence of HBV declines with the implementation of immunization programs and HCV is eradicated by direct acting anti viral therapies, more cases will be due to metabolic causes such as non-alcoholic fatty liver disease. The cornerstone of management involves identifying potential risk factors and implementing both preventative and therapeutic strategies. As we gain more knowledge about the pathogenesis of HCC, newer agents such as multikinase inhibtors have been developed to target specific pathways and have been shown to delay time to disease progression. Well defined screening, diagnostic and management algorithms will allow for standardisation of protocols and enable classification of patients and treatment modalities offering some prediction of outcome and prognosis. It is anticipated that effective screening and surveillance programs will enable the detection of tumours at an early stage thereby allowing for a wider range of therapeutic options with improved outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–16.

    Article  PubMed  Google Scholar 

  2. Robotin MC, George J, Supramaniam R, et al. Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Med J Aust. 2008;188:363–5.

    PubMed  Google Scholar 

  3. Thein HH, Walter SR, Gidding HF, Amin J, Law MG, et al. Trends in incidence of hepatocellular carcinoma after diagnosis of hepatitis B or C infection: a population-based cohort study, 1992–2007. J Viral Hepat. 2011;18(7):e232–41.

    Article  PubMed  CAS  Google Scholar 

  4. Thein HH, Walter SR, Gidding HF, Amin J, Law MG, et al. Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort. Hepatol Res. 2012 Apr 18.

  5. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–50.

    Article  PubMed  CAS  Google Scholar 

  6. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case–control study. J Natl Cancer Inst. 2011;103:1686–95.

    Article  PubMed  Google Scholar 

  7. Deugnier YM, Guyader D, Crantock L, Lopez JM, Turlin B, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology. 1993;104:228–34.

    PubMed  CAS  Google Scholar 

  8. Ioannou G, Splan M, Weiss N, McDonald G, Beretta L, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5:938–45.

    Article  PubMed  Google Scholar 

  9. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–48.

    Article  PubMed  CAS  Google Scholar 

  10. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–8.

    Article  PubMed  Google Scholar 

  11. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, PROVE1 Study Team, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827–38.

    Article  PubMed  CAS  Google Scholar 

  12. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, SPRINT-2 Investigators, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.

    Article  PubMed  CAS  Google Scholar 

  13. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216–24.

    Article  PubMed  CAS  Google Scholar 

  14. Chen CJ, Yang HI, Su J, Jen CL, You SL, REVEAL-HBV Study Group, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.

    Article  PubMed  CAS  Google Scholar 

  15. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer–In HBV (the REVEAL–HBV) Study Group, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–86.

    Article  PubMed  Google Scholar 

  16. • Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53(2):348–56. An extensive review of recent publications examining the effect of treatment induced viral suppression on reducing HCC risk.

    Article  PubMed  CAS  Google Scholar 

  17. Yuen MF, Wong DK, Fung J, Ip P, But D, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135(4):1192–9.

    Article  PubMed  CAS  Google Scholar 

  18. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31.

    Article  PubMed  CAS  Google Scholar 

  19. • Lampertico P, Soffredini R, Invernizzi F, Viganò M, et al. Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 nuc-naïve patients with chronic hepatitis B: a 4-year field practice, multicenter study. J Hepatol. 2012;56(2):S206–S207. The largest real life data set of the effect of new generation nucleotide analogues on viral suppression and complications of HBV infection. 10 % of patients with cirrhosis developed HCC despite achieving viral suppression.

  20. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923–8.

    Article  PubMed  Google Scholar 

  21. Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.

    Article  PubMed  Google Scholar 

  22. Jung KS, Kim SU, Ahn SH, Park YN, Kim do Y, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology. 2011;53:885–94.

    Article  PubMed  CAS  Google Scholar 

  23. Bridges JF, Joy SM, Gallego G, Kudo M, Ye SL, et al. Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev. 2011;12(10):2585–91.

    PubMed  Google Scholar 

  24. Third National Hepatitis C Strategy 2010–2013 http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-national-strategies-2010-hcv/$File/hcv.pdf

  25. First National Hepatitis B Strategy 2010–2013 www.health.gov.au http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-national-strategies-2010-hepb/$File/hepb.pdf

  26. Gidding HF, Topp L, Middleton M, Robinson K, Hellard M, et al. The epidemiology of hepatitis C in Australia: notifications, treatment uptake and liver transplantations, 1997–2006. J Gastroenterol Hepatol. 2009;24(10):1648–54.

    Article  PubMed  Google Scholar 

  27. Butler J, Korda R, Watson KJ, Watson D. The impact of chronic hepatitis B in Australia: projecting mortality, morbidity and economic impact. Canberra: Australian Centre for Economic Research on Health; 2009.

    Google Scholar 

  28. Wallace J, McNally S, Richmond J. National hepatitis B needs assessment. Melbourne: Australian Research Centre in Sex, Health and Society, La Trobe University; 2008.

    Google Scholar 

  29. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36(6):1349–54.

    PubMed  Google Scholar 

  30. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135(1):111–21.

    Article  PubMed  CAS  Google Scholar 

  31. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22.

    PubMed  Google Scholar 

  32. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen. 2003;10:204–9.

    Article  PubMed  Google Scholar 

  33. Wong N, Haydon A, Kemp W, Wijeratne P, Roberts S. Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995–2009. Intern Med J. 2012. doi:10.1111/j.1445-5994.2012.02755.x.

  34. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, et al. Meta- analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37–47.

    Article  PubMed  CAS  Google Scholar 

  35. Sarasin FP, Giostra E, Hadengue A. Cost–effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child–Pugh class A cirrhosis. Am J Med. 1996;101:422–34.

    Article  PubMed  CAS  Google Scholar 

  36. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. AASLD practice guidelines. Hepatology. 2011;53(3):1020–2.

    Article  PubMed  Google Scholar 

  37. • EASL-EORTC Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56:908–41. A thorough and up to date review of current literature provides the framework for these evidence based guidelines. Covers surveillance, diagnosis and treatment practice summaries.

  38. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325–35.

    Article  PubMed  Google Scholar 

  39. Sinclair M, Roberts S, Kemp W, Knight V, Dev A, et al. For the Melbourne collaboration for the study of Hepatocellular carcinoma. Hepatitis B associated Hepatocellular carcinoma in Melbourne occurs predominantly in cirrhosis. J Gastro Hepatol. 2010;25:S3, A125.

    Google Scholar 

  40. Yu MW, Hsu FC, Sheen IS, Chu CM, Lin DY, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol. 1997;145(11):1039–47.

    Article  PubMed  CAS  Google Scholar 

  41. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28(6):930–8.

    Article  PubMed  CAS  Google Scholar 

  42. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1):77–82.

    PubMed  CAS  Google Scholar 

  43. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003;39:1076–84.

    Article  PubMed  Google Scholar 

  44. Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 2001;20:99–104.

    PubMed  CAS  Google Scholar 

  45. Sato T, Tateishi R, Yoshida H, Ohki T, Masuzaki R, et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int. 2009;3:544–50.

    Article  PubMed  Google Scholar 

  46. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61:317–28.

    Article  PubMed  CAS  Google Scholar 

  47. McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32:842–6.

    Article  PubMed  CAS  Google Scholar 

  48. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, et al. Des-gamma- carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–9.

    Article  PubMed  CAS  Google Scholar 

  49. Sterling RK, Jeffers L, Gordon F, Sherman M, Venook AP, et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol. 2007;102:2196–205.

    Article  PubMed  Google Scholar 

  50. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418–24.

    Article  PubMed  Google Scholar 

  51. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101(3):513–23.

    Article  PubMed  CAS  Google Scholar 

  52. Sersté T, Barrau V, Ozenne V, Vullierme MP, Bedossa P, et al. Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology. 2012;55(3):800–6.

    Article  PubMed  Google Scholar 

  53. Roskams T. Anatomic pathology impact on prognosis and response to therapy. Clin Liver Dis. 2011;15:245–59.

    Article  PubMed  Google Scholar 

  54. Gonzalez SA, Keeffe EB. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy. Clin Liver Dis. 2011;15(2):297–306.

    Article  PubMed  Google Scholar 

  55. Forner A, Reig ME, de Lope CR, Bruix J. Current strategies for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010;30:61–74.

    Article  PubMed  CAS  Google Scholar 

  56. Arii S, Yamaoka Y, Futagawa S, Inoue K, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology. 2000;32:1224–9.

    Article  PubMed  CAS  Google Scholar 

  57. Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, et al. Resection of Hepatocellular cancer ≤ 2 cm: results from two Western centers. Hepatology. 2012. doi:10.1002/hep.25832.

  58. Chua T, Saxena A, Chu F, Liauw W, Zhao J, et al. Clinicopathological determinants of survival after hepatic resection of hepatocellular carcinoma in 97 patients-experience from an Australian hepatobilary unit. J Gastrointest Surg. 2010;14:1370–80.

    Article  PubMed  Google Scholar 

  59. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  PubMed  CAS  Google Scholar 

  60. • Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17:S44–57. The first systematic review of Milan criteria confirming that patients meeting the Milan criteria have similar survival to those been transplanted for non malignant conditions.

    Article  PubMed  Google Scholar 

  61. Yao FY, Ferrell L, Bass NM, Watson JJ, Bachetti P, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumour size limits does not adversely impact survival. Hepatology. 2001;33:1394–403.

    Article  PubMed  CAS  Google Scholar 

  62. The Transplantation Society of Australia and New Zealand. Organ transplantation from deceased donors: consensus statement on eligibility criteria and allocation protocols version 1.1. 23 June 2011.

  63. Cho YK, Kim JK, Kim MY, Rhim H, et al. Systematic review of randomised trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–9.

    Article  PubMed  Google Scholar 

  64. Livraghi T, Meloni F, Di Stasi M, Rolle E, et al. Sustained complete response and complication rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice. Hepatology. 2008;47:82–9.

    Article  PubMed  Google Scholar 

  65. Gory I, Fink M, Bell S, Gow P, Nicoll A, et al. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma- a large multicentre study. J Hepatol. 2012;56:S392.

    Article  Google Scholar 

  66. Llovet JM, Bruix J. Systematic review of randomised trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.

    Article  PubMed  CAS  Google Scholar 

  67. Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit. J Hepatol. 2012;56(4):984–6.

    Article  PubMed  Google Scholar 

  68. Lammer J, Malagari K, Vogi T, et al. Prospective randomised study of doxorubicin eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.

    Article  PubMed  Google Scholar 

  69. Camma C, Shepsis F, Orlando A, et al. Transarterial emobolization for unresectable hepatocellular carcinoma: meta analysis of randomised controlled trials. Radiology. 2002;224:47–54.

    Article  PubMed  Google Scholar 

  70. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolization for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev. 2011;3:CD004787.

    PubMed  Google Scholar 

  71. Radiologist Approach to Transarterial Embolisation (RADIATE) study. Melbourne Collaboration for the study of Hepatocellular carcinoma.

  72. • Salem R, Lewandowski R, Kulik L, Wang E, Riaz A, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507. A comparative study of TACE and Radioembolization which demonstrates similar survival, but better side effect profile in the RE group. The authors state a RCT designed to compare the two modalities would need >1000 patients to be adequately powered and may not be the best use of resources.

    Article  PubMed  Google Scholar 

  73. Kulik LM, Carr BI, Mulcahy MF, Lewandowski R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.

    Article  PubMed  Google Scholar 

  74. Llovet JM, Ricc S, Mazzaferro V, Hilgard P, Gane E, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  PubMed  CAS  Google Scholar 

  75. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma :a phase III randomised, double blind, placebo- controlled trial. Lancet Oncol. 2009;10(1):25–34.

    Article  PubMed  CAS  Google Scholar 

  76. Roberts SK, Kemp W. Hepatocellular carcinoma in an Australian tertiary referral hospital 1975–2002: change in epidemiology and clinical presentation. J Gastro Hepatol. 2007;22:191–6.

    Article  Google Scholar 

  77. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140:1410–26.

    Article  PubMed  CAS  Google Scholar 

  78. Lencioni R, Zou J, Leberre M, et al. Sorafenib(S) or Placebo(P) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma(SPACE) J Clin Oncol. 2010;28 (suppl :abstrTPS178).

  79. Chemoembolization with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. http://www.clinicaltrials.gov/ct2/show/NCT01004978&rank=1.

  80. Abou-Alfa GK. TACE and Sorafenib: a good marriage? J Clin Oncol. 2011;29:3949–52.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria, 3168, Australia

    Anouk Dev & Virginia Knight

  2. Department of Medicine, Monash University, 246 Clayton Road, Clayton, Victoria, 3168, Australia

    Anouk Dev & Virginia Knight

Authors
  1. Anouk Dev
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Virginia Knight
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anouk Dev.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dev, A., Knight, V. Screening and Management of Hepatocellular Carcinoma: The Australian Perspective. Curr Hepatitis Rep 11, 197–205 (2012). https://doi.org/10.1007/s11901-012-0151-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-012-0151-5

Keywords

Search

Navigation